Scale and optimize your transfection in a closed system with the CTS Xenon Electroporation System

Closed manufacturing of cell therapies is widely accepted as an effective way to create a safer therapeutic product through reduction of error often associated with traditional manual cell processing techniques. In addition to closing manufacturing systems, the industry is moving toward targeted gene delivery methods such as transfection with CRISPR-Cas9 to achieve both performance and safety enhancements over traditional random integration of vectors.

Download now to learn more about CTS Xenon Electroporation System that enables transition from research to commercial manufacturing by facilitating scalable and flexible nonviral delivery for cGMP cell therapy processing.